ArticleBlood cancer discovery2026
Safety and Clinical Outcomes of a First-in-Human Trial of Point-of-Care Manufactured Trispecific CAR T Cells Targeting CD19, CD20, and CD22.
Sumithira Vasu et al.PubMed ↗Publisher ↗
No numbers read from the abstract.